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            Congestive heart failure (CHF) is a common, debilitating and usually lethal condition 
responsible for enormous burden on health care. The recent trials have shown improvement in 
morbidity and mortality with ACE inhibitors and beta blockers1-3. However, despite this the 
overall prognosis remains dismal. The other alternative of cardiac transplantation has several 
limitations including the donor organ scarcity. In view of this gloomy prognosis, several 
alternative strategies are being explored, one of which has been pacing for heart failure. In this 
form of therapy pacing is used in absence of the conventional bradyarrhthymic  indications with 
an attempt to lead to optimization of AV delay and co-ordination of ventricular contraction.       
            In 1990, Hochleitner et al4 reported clinical improvement in patients with severe heart 
failure awaiting cardiac transplantation with implantation of a physiologic dual-chamber 
pacemaker (pacing at right atrium and right ventricle) with a programmed short atrioventricular 
(AV) delay. Brecker et al5 in 1992 reported similar observations. However, in a randomized 
cross over design,with larger number of patients there was no significant improvement in the 
NYHA class or ejection fraction6. Sack et al7 and Guide et al reported similar negative results. 
Consequently, it is difficult to advocate dual chamber pacing for heart failure management.         
          The reasons for the discrepancies in the results of these studies is possibly due to the 
detrimental effect of pacing induced broadening of the QRS complex duration in severe 
ventricular disease resulting from Right Ventricular (RV) apical pacing offsetting the beneficial 
effect of increased ventricular filling time. As a result the focus has now shifted to Left 
Ventriuclar (LV) or biventricular (BiV) as opposed to RV pacing supplemented with the lessons 
learnt from the optimization of the AV delay.
Electromechanical Cardiac Synchrony                                                                                     
              The association of asynchronous ventricular contraction with ventricular dysfunction 
has been recognized for many years. In recent years the presence of left bundle branch block 
(LBBB) has been shown to correlate with decreased LV function, reduced peak dp/dt. LBBB 
results in asynchronous ventricular contraction with the LV lateral wall contracting much later 
that the inverventricular septum in addition there is an RV-LV asynchrony with RV contracting 
earlier   than   LV.                                                                                          
               The presence of conduction disturbances is seen in 20-30% of the patients with 
congestive heart failure and contributes to the worsening of symptoms due to improper co-
ordination of LV contraction. 
Cardiac Resyndronisation Therapy (CRT)                                                                                         
           CRT aims at 3 different levels (a) AV level (b) intraventricular level (c) interventricular 
level. At present this is achieved by pacing or sensing the right atrium, pacing the right ventricle 
(near the interventricular septum) and pacing the left ventricle (using the coronary venous 
branches), also called biventricular pacing.
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Left Ventricular Lead Design                                                                                                   
            The present LV leads have lower profile with preformed curves. Most of the leads 
followed the same conventional central-stylet technology, with curves being fashioned to 
negotiate the variabilities in cardiac vein anatomy.   Recently over-the-wire lead deployment 
systems have been developed (Easytrak - Guidant Corporation, St. Paul, MN) and have the 
procedure like an angioplasty. Overall, the success rate for implantation of left-sided leads 
ranges from 75 to 93%.
Implantation Technique                                                                                                                       
           The implantation of biventricular pacing is more technically challenging than a dual 
chamber pacing for the reason of placing the LV pacing lead appropriately. Prior to the 
introduction of the endocardial LV pacing leads, surgical implantation of these leads epicardially 
was   the   norm.                                                                                                  
            It is now possible to pace by entering the cardiac veins which are approached through the 
coronary sinus and obtain a reasonable threshold in one of the cardiac veins. The presence 
number, location, size and tortousity of posterior and lateral branches is usually variable. The 
coronary veins are thus studied by contrast injections with a balloon inflated catheter within the 
coronary sinus and subsequently the lead can be placed precisely. The posterolateral veins yield 
the best haemodynamic outcome and are the ones targeted for the placement of LV leads.           
            The findings from the PATH - CHF trial9 suggest that increases in pulse pressures and 
DP/DT max were maximum at the mid lateral epicardial pacing sites compared with other 
regions of the left ventricle, consequently posterolateral sites are currently targeted for left 
ventricular pacing. Kass et al10 in 1999 demonstrated that LV single site pacing was equal or 
superior to biventricular pacing. Further studies would be needed to demonstrate whether LV 
pacing is equivalent. It is possible that LV pacing may not maintain LV/RV syndrony due to 
earlier pacing of the LV site.
Identifying patients likely to respond                                                                                     
            The primary variable has been the QRS duration - an electrial marker for spatially 
dispersed mechanical activation.8  A QRS duration of more than 150ms with class 3 or 4 
congestive heart failure and low left ventricular ejection fraction is an accepted indication for 
left ventricular pacing. In presence of QRS duration of 120-150msec, certain echo - doppler 
variables must be noted (such as Q to aortic flow velocity or interventricular dysynchrony - Q to 
aortic flow - Q to pulm flow) to obtain the maximum benefit.
Acute Clinical Studies                                                                                                     
           Several studies have studied the effects of BiV pacing on the acute haemodynamics. It 
has been seen that BiV pacing improves cardiac output and enhances ventricular systolic 
function as assessed by maximal rate of pressure rise and pressure volume loops. Furthermore 
this improvement in LV systolic function occurs while concomitantly reducing myocardial 
oxygen consumption.
Chronic Clinical Studies                                                                                                                   
            Three placebo control studies have been completed - the PATH - CHF trial9, the 
MUSTIC trial11 and the MIRACLE trial12. In the PATH-CHF study, patients were first assigned 
to four weeks of active pacing (LV or BiV), then four weeks of no pacing, then a second four-
week active pacing period-continued for the ensuing year. This was a single-blind study and 
required surgically implanted leads and two stimulators. Importantly, exercise performance (e.g., 
maximal oxygen consumption) rose significantly only during the two periods of active pacing. 
This finding in the third month (after a month of no-pacing) was somewhat more difficult to 
ascribe to a placebo effect.
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             The recently published MUSTIC study11  used a cross-over design, with patients 
randomized to three months’ stimulation on or off and the mode then switched for the second 
three-month period. In sinus rhythm patients, exercise capacity improved olnly during active 
treatment (+23% in 6-min walking distance, p < 0.001), improved symptoms (32% in quality-of-
life questionnaire, p < 0.001) and increased maximal oxygen consumption (+8%, p < 0.03). 
Interestingly, this study did not observe a placebo effect. A separate component of this study 
evaluated patients with chronic atrial fibrillation, each patient under-going AV nodal ablation 
prior   to  receiving  a   BiV   stimulation  system.   Intention-to-treat   analysis   failed  to  reveal 
significant differences between pacing on and off data, although limitations due to study design 
and loss of effective pacing in several subjects contributed to this. In the subset of subjects in 
which pacing was effectively delivered, the results suggested improvement, but this needs more 
definitive testing.                                                                                                     
           The recently completed MIRACLE trial12 is the largest study to date. Preliminary data 
have been reported and a full publication is pending. This six-month parallel-design trial 
randomized 228 patients to resynchronization therapy and another 225 patients to a placebo 
control arm. All patients were in normal sinus rhythm and were stable NYHA functional class 
III or class IV. The primary findings showed an improvement in the 6-min walk test, quality-of-
life score, and NYHA functional class (a combined end point was also examined). Secondary 
end points were also assessed in a subset of patients, and the data support a diminished diastolic 
and systolic chamber size in the active resynchronization treatment but not in the placebo group. 
Mortality was <10% in both treatment arms at six months. Rehospitalization rates and number of 
days hospitalized were both significantly and substantially lower in the active treatment group. 
The investigators reported a placebo effect with respect to quality of life but not for exercise or 
cardiac-function parameters.
 Unresolved Issues, Future Directions                                                                                         
           Clearly, there are major important questions about whether there is a sustained benefit on 
morbidity and reduced hospitalization and whether there is a favorable effect on overall and 
cardiac mortality. In this regard, it is important that the ongoing trails such as COMPANION, 
which are addressing these key questions, proceed to completion so that the role of this therapy 
can be properly and fully evaluated. The mortality impact of resynchronization may ultimately 
be tied in with ICDs, particularly if the results of ongoing multicenter trials show survival 
benefits   from  such  devices   in  HF.                                                                        
          Another question relates to the prospective identification of responders. New methods 
examining regional wall motion hold promise for generating a dyssynchrony index that could 
improve on current, more indirect methods. The optimal method of therapy itself is unresolved. 
As noted, questions remain as to whether BiV stimulation is needed, whether multisite left-heart 
stimulation would enhance the efficacy, or, if an RV lead is to be placed, where the optimal 
location is and what the best timing delay is between RV and LV stimulation.                     
           A large unresolved question is whether this therapy is going to be useful in patients with 
atrial fibrillation. Some studies have suggested utility, although larger trial data remain 
inconclusive. Unlike the sinus rhythm patients, in which there is some degree of freedom in the 
AV delay to optimally time a resynchronization effect, the AV node in atrial fibrillation patients 
is generally ablated, and then patients are treated using a BiV pacing mode. This involves 
regularization of the heart rate with rate-responsive generators, as well as activation of both 
lower chambers. Rate response serves to simulate normal effects of autonomic tone, but it is not 
a perfect replacement for physiologic control. Furthermore, in patients without an existing 
conduction delay, BiV pacing may not yield as good a response as that with His-Purkinje 
conduction. More studies are clearly needed in these patients.                                 
           Finally, the existing evidence indicating deterioration of systolic function and energetic 
efficiently with pacing-induced dyssynchrony suggests that standard RV apex pacing in 
individuals with cardiac failure may not be the ideal approach. In patients with cardiodepression 
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but a narrow QRS complex and normal intraventricular conduction who need pacing for rate 
control, a BiV system may prove superior, but this clearly needs to be tested.
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